Minerva Neurosciences, Inc. (NASDAQ:NERV) Shares Bought by Northern Trust Corp

Northern Trust Corp grew its position in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,878 shares of the biopharmaceutical company’s stock after acquiring an additional 13,829 shares during the quarter. Northern Trust Corp owned about 0.53% of Minerva Neurosciences worth $82,000 as of its most recent filing with the SEC.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NERV shares. Wall Street Zen started coverage on shares of Minerva Neurosciences in a report on Wednesday, May 21st. They set a “sell” rating for the company. HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Stock Up 12.5%

NERV stock opened at $1.76 on Wednesday. The company has a market capitalization of $12.27 million, a P/E ratio of -3.99 and a beta of -0.50. The company has a 50-day simple moving average of $1.57 and a 200 day simple moving average of $1.89. Minerva Neurosciences, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.57. Equities analysts anticipate that Minerva Neurosciences, Inc. will post -0.3 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.